Vivonics offers a rapid, simple in vivo model for evaluating the effects of drug candidates on cardiac electrophysiology. ECGs are recorded in anaesthetised guinea pigs and drug-induced effects on QT interval and other aspects of cardiac electrophysiology are measured. This is a well-established and relevant model in preclinical cardiac safety testing as this species has a cardiac ion channel profile and ECG comparable to that of humans. Simultaneous measurements of haemodynamic parameters and cardiac function are performed and effects on these parameters also show good concordance with human data. Pharmacokinetic samples are generated alongside the cardiovascular data enabling PK/PD relationships to be derived.
The small compound requirement of the assay make it ideal for use during lead optimisation when de-risking projects prior to more expensive regulatory studies. The single in vivo screen provides a significant amount of information which we interpret for our clients. We will also integrate the data with other relevant project information (e.g. in vitro data, ion channel data, predicted human concentrations).
The effect of a calcium channel blocker (verapamil) on an index of cardiac contractility (Vivonics data)
Vivonics Preclinical Ltd,BioCity Nottingham
The effect of a hERG channel blocker (dofetilide) and multichannel blocker (ranolazine) on QTc interval (Vivonics data)